Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: News

Tribun Health Achieves FDA Clearance for CaloPix Digital Pathology Platform With Dual Scanner Compatibility

Paving the way for U.S. Market Entry and Global Expansion

PARIS, FRANCE / ACCESS Newswire / May 20, 2025 / Tribun Health, a leader in digital pathology, proudly announces that its flagship web-based image management system, CaloPix®, has received FDA 510(k) clearance for use with two leading whole slide imaging scanners: the Hamamatsu NanoZoomer S360 and the Leica Aperio GT450. This marks the first time a digital pathology software has been cleared with both scanners, representing a major step forward for the U.S. adoption of vendor-agnostic, enterprise-grade solutions.

Pathologist Using CaloPix® for Digital Slide Review
A pathologist reviews high-resolution whole slide images on CaloPix® at her workstation. The platform’s intuitive, web-based interface enables seamless case navigation, diagnostic annotation, and real-time collaboration—empowering clinicians to make

This clearance builds on CaloPix’s strong regulatory track record: the solution is CE-marked, Health Canada-approved, and trusted by more than 100 hospitals and laboratories across Europe and Canada. With over 1,000 active users of CaloPix® worldwide, this milestone underscores the platform’s scalability, clinical reliability, and rapid adoption across diverse healthcare systems. Now, with FDA clearance secured, Tribun Health is ready to bring its proven enterprise solution to hospitals and labs across the United States.

Besides these regulatory achievements, CaloPix® has also been recognized three times as “Best in KLAS” for digital pathology, a global benchmark for excellence in healthcare IT. This prestigious recognition highlights Tribun Health’s commitment to customer satisfaction, operational excellence, and product innovation.

“This is a major commercial and clinical milestone for us,” said Jean-François Pomerol, CEO of Tribun Health. “We’re entering the U.S. with a solution that has already proven its value in demanding, high-throughput clinical environments. With CaloPix®, we offer a platform trusted by top-tier institutions, awarded Best in KLAS multiple times -and now validated by the FDA. As the market accelerates toward widespread clinical adoption, we’re thrilled to expand our reach and solidify our position as a truly global player.”

Built for Enterprise, Designed for Performance, Ready for Cloud

CaloPix® goes far beyond a traditional image viewer-it’s a powerful, all-in-one digital pathology platform tailored for the needs of modern healthcare systems, large hospital networks, and academic institutions.

Key capabilities include:

  • Web-based, Cloud ready, zero-footprint architecture-no local installation required

  • High-throughput case management and diagnostic reporting to streamline daily workflows

  • Seamless integration with LIS and VNA systems for unified data access across the enterprise

  • Built-in telepathology and remote collaboration tools for second opinions and network-wide consultations

  • Archiving, export, and quality control features to support regulatory compliance and research initiatives

Meeting the Moment: Solving U.S. Market Challenges

The U.S. faces a growing mismatch between rising pathology case volumes and a shrinking workforce. At the same time, there is a clear push for multi-site collaboration, integrated diagnostics, and precision medicine initiatives.

With this FDA clearance, CaloPix® empowers U.S. hospitals and labs to:

  • Digitize pathology workflows at scale

  • Reduce turnaround times and improve reporting accuracy

  • Collaborate remotely across institutions

  • Prepare for AI adoption with structured, interoperable data

Building on our success with public health networks, cancer centers, academic hospitals and private laboratory groups across Europe and Canada, we are now ready to scale in the world’s largest healthcare market-the United States.

* CaloPix® is CE mark, HC cleared, FDA cleared. Please refer to IFU for intended use.

About Tribun Health

Tribun Health is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X.

Contact Information

Andreia Beyer
VP, Global Marketing & Managing Director, North America
abeyer@tribun.health
+1 (416) 565-0474

SOURCE: Tribun Health

View the original press release on ACCESS Newswire

Staff

Recent Posts

Wealthy Americans Drive Nearly One-Third of Global Citizenship Demand: USA Spotlight

LONDON, UK / ACCESS Newswire / August 21, 2026 / US nationals accounted for nearly…

28 minutes ago

IRA-Eligible Gold: Rules, Approved Coins, and Best Gold Dealers (Guide Released)

To help consumers get a better understanding of Gold IRA rules, IRAEmpire has released its…

29 minutes ago

Kiwi Ears Stardust: The Art of Natural Balance

The Kiwi Ears Stardust combines a dynamic driver with four balanced armature drivers to deliver…

29 minutes ago

NPTA Launches International I.M.P.A.C.T. Awards to Recognize Pharmacy Technicians Advancing Patient Care and Pharmacy Practice

New international awards program honors measurable contributions to medication safety, patient access, innovation, education and…

29 minutes ago

PPX Mining Announces Completion of Debt Settlement

TORONTO, ON / ACCESS Newswire / August 20, 2026 / PPX Mining Corp. ("PPX" or…

29 minutes ago

What The Washington Post and Mark Robichaux Got Wrong About Menhaden

WASHINGTON, D.C. / ACCESS Newswire / August 20, 2026 / The Washington Post today published…

29 minutes ago